Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People who have been diagnosed with stage IV lung adenocarcinoma (a type of lung cancer) that has a specific genetic change called an ALK rearrangement, and whose cancer has continued to grow after treatment with a medicine called alectinib as the first treatment
• People who have at least one area of cancer in the body that can be measured on a scan, as determined by the trial site's medical team (areas that have previously been treated with radiation therapy for pain relief cannot be used as the measured target)
• People who have 20 prepared tissue samples from a previous biopsy available; those who do not have suitable tissue samples on file will need to have a new biopsy performed to provide a tissue sample
• People whose physical ability and daily functioning is rated at 0 or 1 on a standard scale used by doctors (meaning they are either fully active or have minor limitations but can carry out light activity)
• People with a life expectancy of at least 3 months
• People with adequate blood counts and organ function, as determined by the trial site (confirm with trial site)

Who may not be able to join:

• People who have cancer that has spread to the brain or spinal cord that is either currently active or has not yet been treated
• People who have had a different cancer (other than the type of lung cancer this trial focuses on) within the past 5 years, unless that cancer carried very little risk of spreading or causing death and was treated with the intention of a cure
• People who are pregnant or currently breastfeeding
• People who have an active autoimmune disease (where the immune system attacks the body) that has required medication to treat it at any point in the past 2 years
• People who have a history of certain lung conditions, including idiopathic pulmonary fibrosis, organising pneumonia, drug-induced lung inflammation, or unexplained lung inflammation — or who show signs of active lung inflammation on a chest scan at the time of screening (a history of scarring from radiation in a treated area is acceptable)
• People who have tested positive for HIV
• People who have active hepatitis B or hepatitis C infection
• People who have had a serious infection within the 4 weeks before joining the trial
• People who have significant heart or cardiovascular disease (confirm with trial site for specific conditions)
• People who have an illness or condition that would prevent them from understanding or following the trial procedures
• People who are currently taking part in another clinical trial involving an experimental treatment, or who have received an experimental treatment or used an experimental medical device within 4 weeks before the first dose in this trial
• People who have previously been treated with certain types of immunotherapy medicines known as anti-PD-1 or anti-PD-L1 antibodies, or with medicines that target a protein called VEGF

Important: Always verify eligibility with the trial site directly before applying.